Triple-Drug cocktail targets tough lung cancer
NCT ID NCT04958811
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This phase 2 study tests whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab can shrink tumors in people with advanced non-squamous lung cancer that has worsened after prior treatment. The trial enrolls 29 adults whose tumors have certain genetic features. Researchers will measure how many patients respond and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tiragolumab, atezolizumab, and bevacizumab (three drugs given together intravenously every 3 weeks)
What this could lead to
If it works, this could offer a new treatment option for people with advanced non-squamous lung cancer who have already tried other therapies.
What could go wrong
This is a small, early-phase study (29 people) with no control group, so results may not apply broadly. The drug combination can cause serious side effects like immune-related inflammation or bleeding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.